Month: March 2022

Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

Written by Customer Service on March 28, 2022. Posted in Earnings Releases And Operating Results.

Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or chemotherapyExpected readouts for Phase 1b trial in p53-mutated non-small cell lung cancer (NSCLC): Interim data in 2Q22; topline results in 4Q22 Anticipated milestones for planned Phase 1b clinical trial in p53-mutated neoadjuvant breast cancer: Initiation in 1H22; interim results in 4Q22Cash, cash equivalents and investments as of December 31, 2021 expected to fund operations into the fourth quarter of 2023BOSTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today...

Stratus Properties Inc. and Ryman Hospitality Properties, Inc. Provide Update on Anticipated Closing Date for Sale of Block 21

Written by Customer Service on March 28, 2022. Posted in Mergers And Acquisitions.

NASHVILLE, Tenn., March 28, 2022 (GLOBE NEWSWIRE) — Stratus Properties Inc. (NASDAQ: STRS) (“Stratus”) and Ryman Hospitality Properties, Inc. (NYSE: RHP) (“Ryman”) announced today that the anticipated closing date for the previously announced sale of Block 21 by Stratus to Ryman has been extended, as the parties complete the process of obtaining the remaining required approvals of the assumption of the property’s existing mortgage loan by the purchaser. The acquisition is now expected to close sometime prior to June 1, 2022, subject to the timely satisfaction or waiver of various closing conditions, including the final consent of the loan servicers to the assumption of the existing loan by the purchaser, the consent of the hotel operator, an affiliate of Marriott, to the assumption of the hotel operating agreement by the purchaser,...

U.S. Energy Corp. Announces Full Year and Fourth Quarter 2021 Results; Declares First Quarterly Cash Dividend Payment

Written by Customer Service on March 28, 2022. Posted in Dividend Reports And Estimates.

HOUSTON, March 28, 2022 (GLOBE NEWSWIRE) — U.S. Energy Corp. (NASDAQCM: USEG) (“U.S. Energy” or the “Company”) today announced results for the full year and fourth quarter ended December 31, 2021. In addition, the Company’s board of directors declared a quarterly cash dividend of $0.0225 per share of common stock, payable on May 2, 2022, to shareholders of record as of April 15, 2022. HighlightsExecuted Purchase and Sale Agreements for previously announced transformative acquisitions on October 4, 2021, which closed subsequent to year-end on January 5, 2022; Full year 2021 production of 123,165 barrel of oil equivalent (“BOE”), or average daily production of 337 BOEPD, an increase of 55% compared to full year 2020; Full year 2021 revenue of $6.7 million, an increase of 186% compared to full year 2020; 4Q2021 production of 31,929...

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Written by Customer Service on March 28, 2022. Posted in Public Companies.

Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety and tolerability profile observed in heavily pre-treated patients Pivotal study initiation expected 2H 2022 following food effect study CAMBRIDGE, Mass., March 28, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced clinical and regulatory updates on its lead program, CLN-081. CLN-081 is being evaluated in an ongoing Phase 1/2a clinical trial in non-small cell lung cancer (NSCLC) patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have progressed on or after prior therapy. Clinical Update: In the ongoing Phase 1/2a study, CLN-081...

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results

Written by Customer Service on March 28, 2022. Posted in Earnings Releases And Operating Results.

RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include:Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter. Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods. For the full year, net loss was $16.6 million and Adjusted EBITDA1 loss was $8.7 million, improvements of 17.9% and 21.2%, respectively. As announced March 16, 2022, Marrone Bio and Bioceres Crop Solutions (NASDAQ: BIOX) have entered into a definitive agreement to combine the companies in an all-stock transaction.Selected Financial Highlights...

Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 28, 2022. Posted in Earnings Releases And Operating Results.

Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company’s Targeted Therapeutics Clinical Programs with Initiation of Clinical Device Performance Study in Patients with Ulcerative Colitis Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2021. In the fourth quarter Progenity made important progress in transforming into an innovation-led biotherapeutics company initially focused on its targeted and systemic biotherapeutics platforms. The strategy of achieving rapid induction and remission...

Gildan Announces First Sustainability-Linked Loan

Written by Customer Service on March 28, 2022. Posted in Public Companies.

(all amounts are in U.S. dollars except where otherwise indicated)1 Compare to a 2018 baseline MONTREAL, March 28, 2022 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL: TSX and NYSE) is pleased to announce that it has signed an amended and restated credit agreement in respect of its existing $ 1 billion revolving credit facility to incorporate sustainability-linked terms, underscoring Gildan’s strong leadership and commitment towards its environmental, social, and governance (ESG) targets. The amendment introduces an annual pricing adjustment based on the achievement of three of Gildan’s Next Generation ESG targets, which were communicated at the beginning of this year. Gildan is the first Canadian apparel manufacturing company to tie financing costs to the achievement of important ESG targets. “Sustainability is a key pillar...

CORRECTING and REPLACING — QuoteMedia Year End 2021 Financial Results and Investors’ Conference Call March 30, 2022

Written by Customer Service on March 28, 2022. Posted in Public Companies.

PHOENIX, March 28, 2022 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by QuoteMedia, Inc. (OTCQB: QMCI), please note that the Dial-in number should be 866-831-8713, not 866-518-6930 as previously stated. The corrected release follows: QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, today announced that its earnings for its year ended December 31, 2021 will be released the morning of March 30, 2022. That same day, the company will host a conference call at 2:00 PM Eastern time to discuss the financial results and provide a business update. Conference Call Details: Date: March 30, 2022 Time: 2:00 PM Eastern Dial-in numbers: 866-831-8713 Conference ID: QUOTEMEDIA An audio rebroadcast of the call will be available later at: www.quotemedia.com. About QuoteMedia...

Tintina Announces Execution of Royalty Repurchase Agreement

Written by Customer Service on March 28, 2022. Posted in Public Companies.

TORONTO, March 28, 2022 (GLOBE NEWSWIRE) — Tintina Mines Limited (“Tintina” or the “Company”) (TSX VENTURE: TTS) is pleased to announce that it has entered into a royalty repurchase agreement, with an effective date of March 17, 2022, and signed on March 25, 2022, with Canadian Malartic GP (“CMGP”), an Ontario general partnership, in which CMGP will exercise its buy-out option to repurchase the 2% net smelter return royalty held by the Company over the Rand property (the “Buy-Out Option”) for a total purchase price of $7,000,000 (USD). The exercise of the Buy-Out Option by CMGP is also subject to the terms and conditions of an existing Net Smelter Royalty Agreement between the Company and CMGP (the “Royalty Agreement”). The Royalty Agreement was assigned to the Company by NSR Resources Inc. (“NSR”) on April 7, 2020. NSR became...

Nokia Corporation: Repurchase of own shares on 28.03.2022

Written by Customer Service on March 28, 2022. Posted in Public Companies.

Nokia CorporationStock Exchange Release28 March 2022 at 21:00 EET Nokia Corporation: Repurchase of own shares on 28.03.2022 Espoo, Finland – On 28 March 2022 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 249,022 4.92CEUX 10,377 4.92AQEU 10,427 4.91TQEX 5,174 4.92Total 275,000 4.92* Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the current authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in traches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals